[1] Zhu P.Meta-Analysis of the Effects of Recombinant Human Brain Natriuretic Peptides on Left Ventricular Remodeling in Patients with Acute Myocardial Infarction. Comput Math Methods Med. 2022 Aug 18;2022:8916791.
[2] Ning C, Zheng Y, Li J, et al. Effects of recombinant human brain natriuretic peptide in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis.Medicine (Baltimore).2020 Mar;99(11):e19479.
[3] Velagaleti RS, Pencina MJ, Murabito JM, et al.Long-term trends in the incidence of heart failure after myocardial infarction[J].Circulation,2008,118(20): 2057-2062.
[4] Gerber Y,Weston SA, Enriquez-Sarano M, et al.Atherosclerotic burden and heart failure after myocardial infarction[J].JAMA Cardiol, 2016,1(2):156-162.
[5] Najafi F,Dobson AJ,Hobbs M,et al.Late-onset heart failure after myocardial infarction:trends in incidence and survival[J].Eur J Heart Fail,2008,10(8): 765-771.
[6] Juilliere Y,CambouJP,Bataille V, et al.Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry[J].Rev Esp Cardiol (Engl Ed), 2012, 65(4): 326-333.
[7] 杨艳敏,朱俊,谭慧琼,等.中国ST段抬高的急性心肌梗死临床特征及治疗现状[J].中华医学杂志,2005, 85(31): 2176-2182.
[8] Roe MT, Messenger JC, Weintraub WS, et al.Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.J Am Coll Cardiol 2010;56:254-263.
[9] Jernberg T,Johanson P, Held C, et al.Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.JAMA 2011;305:1677-84.
[10] Puymirat E, Simon T, Steg PG, et al.Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction.JAMA 2012;308:998-1006.
[11] Kristensen SD, Laut KG, Fajadet J, et al.Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J,2014;35:1957-1970.
[12] 于晓迪,李红岩,李舸,等.急性心肌梗死后发生心力衰竭患者的早期预测研究进展[J].医学理论与实践,2020,33(17):2805-2806,2804.
[13] Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature.1988 Mar 3;332(6159):78-81.
[14] Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol.2001 Apr;37(5):1221-1227.
[15] Han B, Hasin Y. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther.2003 Jan;17(1):41-52.
[16] Le S, Xiao J, Li W, Wang J, Wang Q, Xi W, Xu J, Wang Z. Continuous administration of recombinant human B-type natriuretic peptide can improve heart and renal function in patients after cardiopulmonary bypass surgery. J Thorac Dis.2017 Mar;9(3):692-701.
[17] Haaf P, Balmelli C, Reichlin T, et al. N-terminal pro B-type natriuretic peptide in the early evaluation of suspected acute myocardial infarction. Am J Med.2011 Aug;124(8):731-739.
[18] Solomon SD, Anavekar N, Skali H,et al; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation.2005 Dec 13;112(24):3738-3744.
[19] Sjöblom J, Muhrbeck J, Witt N, et al. Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility. Circulation.2014 Aug 26;130(9):743-748.
[20] Xu H, Wang B, Meng Q, et al. Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure. Pak J Med Sci.2017 May-Jun;33(3):540-544. doi: 10.12669/pjms.333.12483. PMID: 28811767; PMCID: PMC5510099.
[21] 范孟静,李学强,刘谧,等.注射用重组人脑利钠肽对急性前壁心肌梗死急诊PCI术后合并心力衰竭患者的疗效[J].心血管病防治知识,2023,13(13):3-5. |
